Patent ID: 7423040

Claim:
A pharmaceutical composition comprising an effective amount of an active ingredient comprising a crystalline polymorph of 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate and at least one pharmaceutically acceptable excipient, wherein, following administration of an effective amount of the composition to a human subject, the subject exhibits at least one of: (a) a plasma T max of 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone within at most about 3 hours; (b) a plasma C max of 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone of at least about 0.1 ng/ml; or (c) a plasma AUC 0-24 of 7-[4-([1,1′-biphenyl]-3ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone of at least about 0.9 hr·ng/ml.